UniQuest

What UniQuest does

UniQuest Pty Limited is the wholly-owned research commercialisation company of The University of Queensland (UQ), founded in 1984 and headquartered in Brisbane, Australia. The firm operates as the exclusive conduit for translating UQ's intellectual property into commercial outcomes, providing end-to-end services that include IP protection, licensing negotiation, spin-out company creation, and capital attraction. Its core offerings comprise three layers: (1) commercialisation services for UQ researchers, industry partners, and investors; (2) QEDDI, an in-house small-molecule drug discovery group that has produced candidates such as QED-203 (TRPV6 inhibitor for metastatic castration-resistant prostate cancer); and (3) the UniQuest Extension Fund, a $44M venture vehicle supporting UQ-linked founders.

UniQuest's technology portfolio spans life sciences (Molecular Clamp vaccine platform, Q-Sera RAPClot blood collection), agriculture (Guarani Poll cattle DNA test, Koala SNP genetic marker panel), industrial chemistry (on-site hydrogen peroxide production, PFAS-removal magnetic resin), and physical sciences (VeriQuantix fibre-optic quantum data security). Notable proprietary platform technologies include the Molecular Clamp vaccine architecture, which locks viral surface proteins into their native prefusion conformation, and QED-203, developed through more than 15 years of research at the Queensland Emory Drug Discovery Initiative.

The company generates revenue through upfront fees, milestone payments, and royalties from licensing UQ-developed technologies to industry partners, supplemented by equity stakes in spin-out companies (e.g., Vicebio, Q-Sera, Vaxxas, Ceretas) and returns realised through acquisitions and financings. UniQuest serves three primary segments: UQ researchers seeking commercialisation pathways, industry partners licensing breakthrough technologies, and investors accessing pre-vetted university IP. To date, the firm has created 141 companies, maintained 240+ active licence agreements, raised over $1.25B to bring UQ technology to market, returned over $1B to UQ since 2002, and holds 360+ granted US patents.

Name

UniQuest

Legal name

UniQuest Pty Limited

Website

https://uniquest.com.au

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

101–250 employees

Short description

UniQuest is the wholly-owned research commercialisation arm of The University of Queensland, founded in 1984 and based in Brisbane. It licenses UQ intellectual property, creates spin-out companies, and invests through its $44M Extension Fund, serving researchers, industry partners, and investors.

Ownership category

akta.pro rank

Product category

University Technology Transfer and IP Commercialization

NAICS

Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533), Scientific Research and Development Services (5417), Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533110)

SIC

Patent Owners & Lessors (6794)

akta.pro primary industry

IP Licensing, Transactions & Technology Transfer (BPAHAMAF)

akta.pro secondary industry

Quantum Tech Commercialization, IP, Tech Transfer & Venture Research (HDAGAMAN)

Keywords

• University technology transfer
• IP commercialization
• Drug discovery services
• Biotech investment
• Research licensing

Headquarters

HQ city

Brisbane

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Licensing Revenue: UniQuest generates revenue through licensing university intellectual property to industry partners, including upfront payments, milestone payments, and ongoing royalties from commercialised technologies.
2. Company Creation and Equity: UniQuest creates spin-out companies from university research and maintains equity positions, generating returns through acquisitions and equity exits.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

UniQuest commercializes intellectual property generated at The University of Queensland by licensing technologies to industry, forming startup companies around university research, and investing in research-derived ventures through the UniQuest Extension Fund. Its service portfolio includes QEDDI, a translational drug discovery initiative, alongside a pipeline of biomedical, agricultural, environmental, and engineering technologies such as the Molecular Clamp platform, QED-203, RAPClot, and the Koala SNP toolkit.

Product overview

UniQuest is The University of Queensland's dedicated commercialisation company, operating as a technology transfer and research commercialisation organisation rather than a single product company. Its core offerings include: (1) QEDDI - an internal drug discovery capability for small molecule therapeutics; (2) the UniQuest Extension Fund - a $44M investment vehicle for UQ-linked startups; and (3) a portfolio of licensed technologies including the Molecular Clamp vaccine platform, QED-203 prostate cancer therapy, RAPClot blood collection technology, and various genetic testing tools. UniQuest generates impact by commercialising UQ intellectual property through strategic licensing, company creation, and investment attraction.

Differentiator

Problem solved

Functional benefit

Products and services

• UniQuest Technology Licensing Services Core licensing service that packages University of Queensland research outputs — including the Molecular Clamp platform, QED-203, RAPClot, and Koala SNP — for license to industry partners across pharma, biotech, agriculture, and engineering.

Quantifiable outcome

• US$1.25 billion raised to take university technology to market
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• Ellison Medical InstitutecoreStrategic or Co-development Partner · 18 June 2026Exclusive license agreement to advance QED-203, a novel small molecule therapeutic for metastatic castration-resistant prostate cancer, toward first-in-human studies planned for 2027. EMI brings AI-driven research, preclinical models, and clinical expertise to accelerate development.
• SanofiflagshipStrategic or Co-development Partner · 1 July 2025Acquired Vicebio for US$1.15 billion upfront plus up to US$450 million in milestones - the largest acquisition of IP from an Australian university. Sanofi is advancing the Molecular Clamp vaccine technology for respiratory viruses.
• Q-SeracoreStrategic or Co-development PartnerUQ spin-out company founded by UniQuest in 2012, developing RAPClot technology for blood collection tubes. Supported by Medical Research Commercialisation Fund (Brandon Capital Partners), Uniseed, CSIRO, and Austrade.
• VaxxascoreStrategic or Co-development PartnerUQ spin-out company developing needle-free vaccine delivery platform. Has raised $300 million for its technology. UniQuest sourced OneVentures' investment in Vaxxas.
• CeretascoreStrategic or Co-development PartnerUQ spin-out company commercialising therapeutic ultrasound technology developed at Queensland Brain Institute for treating Alzheimer's disease. Listed on ASX with $8 million IPO.
• CortisonicminorStrategic or Co-development PartnerUQ spin-out developing sonic processing technology to reduce power consumption in edge computing. Selected for 2026 Cicada x Tech23 cohort.
• Queensland Emory Drug Discovery Initiative (QEDDI)flagshipStrategic or Co-development PartnerSmall molecule drug discovery group of UniQuest based at UQ's St Lucia campus. Developed QED-203 and other therapeutic candidates through more than 15 years of research.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• CSIRO (Commonwealth Scientific and Industrial Research Organisation): Australia's national science agency, with a large commercial arm that licenses IP and forms spin-out companies from publicly funded research. Comparable as an Australian public-research commercialisation entity with a similar licensing and equity business model.
• MIT Technology Licensing Office: MIT's office responsible for licensing inventions and negotiating technology transfer agreements arising from MIT research. Direct peer as a long-established, large-research-university TTO that monetises IP through licensing and spin-out support.
• Cambridge Enterprise: University of Cambridge's commercialisation arm, handling IP licensing, spin-out formation, and investment activities from one of the world's leading research universities. Operates the same technology-transfer business model as UniQuest.
• Wisconsin Alumni Research Foundation (WARF): One of the oldest and largest university technology transfer organisations, patenting and licensing University of Wisconsin-Madison inventions. Directly comparable as a non-profit TTO generating licensing revenue and equity from academic research.
• Imperial College Innovations / Imperial College London Tech Transfer: Imperial College London's technology transfer office, handling IP licensing and spin-out formation from a research-intensive STEM university. Direct peer in the UK university TTO peer group.
• Oxford University Innovation: University of Oxford's technology transfer and commercialisation company, with a similar mandate of protecting, licensing and spinning out academic IP through partnerships and equity creation. Directly comparable TTO operating at a global research-intensive university.
• UCL Business (UCLB): University College London's commercialisation company, providing technology transfer, IP protection, spin-out creation and venture investment from UCL research. Directly comparable UK university TTO.
• Stanford Office of Technology Licensing (OTL): Stanford's dedicated technology licensing office that handles invention disclosure, patenting, and licensing from Stanford research. Direct peer to UniQuest in scope and function for a top-tier research university.

Regional players

• NewSouth Innovations (UNSW): University of New South Wales's commercialisation company, protecting and licensing IP from UNSW research. Another Australian university TTO operating in the same regulatory and funding environment as UniQuest.
• Monash University Technology Transfer Office: Monash University's commercialisation arm, handling IP protection, licensing and spin-out creation from Monash research. Closest Australian peer in geographic terms and serves a similarly research-intensive university.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/uniquest
• Xx.com/uniquestuq

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UniQuest